Alpha-9 Oncology Inc. raised $175M in a Series C funding round to advance its robust clinical pipeline of radiopharmaceuticals.

Oct 23, 2024•9 months ago

Amount Raised

$175 Million

Round Type

series c

BostonBiopharmaTherapeuticsBiotechnologyHealth Care

Description

Alpha-9 Oncology Inc. has successfully secured $175 million in an oversubscribed Series C financing round. The funds will be utilized to enhance their clinical pipeline geared towards radiopharmaceutical developments.

Company Information

Company

Alpha-9 Oncology

Location

Boston, Massachusetts, United States

About

Alpha-9 Oncology is a clinical stage radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Alpha-9 Oncology Inc. raised $175M in a Series C funding round to advance its robust clinical pipeline of radiopharmaceuticals.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information